Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: KDN018
MIFTS: 72

Kidney Disease

Categories: Blood diseases, Bone diseases, Genetic diseases, Nephrological diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Kidney Disease

About this section

MalaCards integrated aliases for Kidney Disease:

Name: Kidney Disease 12 6 15 39 17
Renal Failure 74 54 6 39 32
Nephropathy 12 74 29 6
Kidney Diseases 42 44 71
Kidney Failure 42 17 71
Abnormality of the Kidney 29 6
Impaired Renal Function Disease 12
Renal Failure Adverse Event 71
Abnormal Renal Function 71
Kidney Dysfunction 54
Renal Anomaly 54
Renal Disease 54
Nephropathies 15

Classifications:

MalaCards categories:
Global: Genetic diseases
Anatomical: Nephrological diseases Blood diseases Bone diseases
See all MalaCards categories (disease lists)
ICD10: 32


External Ids:

Disease Ontology 12 DOID:557
MeSH 44 D007674
NCIt 50 C3149
SNOMED-CT 67 266612003
ICD10 32 N08 N17-N19 N19
UMLS 71 C0022658 C0035078 C0151746 more
Sources

Summaries for Kidney Disease

About this section
MedlinePlus : 42 Healthy kidneys clean your blood by removing excess fluid, minerals, and wastes. They also make hormones that keep your bones strong and your blood healthy. But if the kidneys are damaged, they don't work properly. Harmful wastes can build up in your body. Your blood pressure may rise. Your body may retain excess fluid and not make enough red blood cells. This is called kidney failure. If your kidneys fail, you need treatment to replace the work they normally do. The treatment options are dialysis or a kidney transplant. Each treatment has benefits and drawbacks. No matter which treatment you choose, you'll need to make some changes in your life, including how you eat and plan your activities. But with the help of health care providers, family, and friends, most people with kidney failure can lead full and active lives. NIH: National Institute of Diabetes and Digestive and Kidney Diseases

MalaCards based summary : Kidney Disease, also known as renal failure, is related to chronic kidney disease and polycystic kidney disease, and has symptoms including polyuria An important gene associated with Kidney Disease is COL4A5 (Collagen Type IV Alpha 5 Chain), and among its related pathways/superpathways are Amoebiasis and AGE-RAGE signaling pathway in diabetic complications. The drugs Acarbose and Hydralazine have been mentioned in the context of this disorder. Affiliated tissues include kidney, endothelial and bone, and related phenotypes are cardiovascular system and homeostasis/metabolism

Disease Ontology : 12 A urinary system disease that is located in the kidney.

Wikipedia : 74 Kidney disease, or renal disease, also known as nephropathy, is damage to or disease of a kidney.... more...

Sources

Related Diseases for Kidney Disease

About this section

Diseases in the Kidney Disease family:

Acute Kidney Failure Renal Infectious Disease
Chronic Kidney Disease Ren-Related Kidney Disease

Diseases related to Kidney Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 3034)
# Related Disease Score Top Affiliating Genes
1 chronic kidney disease 34.2 UMOD PKD2 PKD1 NPHS2 CST3 COL4A5
2 polycystic kidney disease 34.2 UMOD TSC1 PKHD1 PKD2L2 PKD2L1 PKD2
3 autosomal dominant polycystic kidney disease 34.0 TSC1 PKHD1 PKD2L2 PKD2L1 PKD2 PKD1
4 polycystic kidney disease 1 with or without polycystic liver disease 33.9 UMOD TSC1 PKHD1 PKD2L2 PKD2L1 PKD2
5 polycystic kidney disease 4 with or without polycystic liver disease 33.8 UMOD PKHD1 PKD2 PKD1 CEP290
6 cystic kidney disease 33.8 UMOD TSC1 PKHD1 PKD2L2 PKD2L1 PKD2
7 polycystic kidney disease 2 with or without polycystic liver disease 33.7 PKHD1 PKD2L2 PKD2L1 PKD2 PKD1
8 end stage renal disease 33.6 UMOD PKD2 PKD1 NPHS2 CST3 COL4A5
9 autosomal dominant tubulointerstitial kidney disease 33.5 UMOD MUC1
10 nephronophthisis 33.4 UMOD PKHD1 PKD2 PKD1 NPHS2 MUC1
11 polycystic kidney disease 4 33.1 PKHD1 ALB
12 proteinuria, chronic benign 33.0 NPHS2 COL4A5 COL4A4 COL4A3 ALB ACE
13 alport syndrome 33.0 PKD1 NPHS2 COL4A5 COL4A4 COL4A3 ALB
14 glomerulonephritis 32.8 NPHS2 COL4A5 COL4A4 COL4A3 ALB ACE
15 polycystic liver disease 32.7 PKHD1 PKD2L1 PKD2 PKD1 ALB
16 focal segmental glomerulosclerosis 32.7 NPHS2 CRB2 COL4A5 COL4A4 COL4A3 ALB
17 caroli disease 32.6 PKHD1 PKD2 PKD1
18 autosomal recessive alport syndrome 32.6 NPHS2 COL4A5 COL4A4 COL4A3 ACE
19 polycystic liver disease 1 with or without kidney cysts 32.5 TSC1 PKHD1 PKD2 PKD1 MUC1
20 alport syndrome 1, x-linked 32.5 COL4A5 COL4A4
21 membranous nephropathy 32.4 NPHS2 ALB ACE
22 iga glomerulonephritis 32.4 NPHS2 ALB ACE
23 congenital hepatic fibrosis 32.4 PKHD1 PKD1
24 autosomal dominant alport syndrome 32.4 NPHS2 COL4A5 COL4A4 COL4A3
25 nail-patella syndrome 32.3 NPHS2 COL4A4 COL4A3
26 familial nephrotic syndrome 32.3 NPHS2 CRB2 COL4A5 COL4A4 COL4A3 ALB
27 anuria 32.3 CST3 ALB ACE
28 potter's syndrome 32.3 PKHD1 ACE
29 goodpasture syndrome 32.2 COL4A5 COL4A4 COL4A3 ALB
30 kidney papillary necrosis 32.1 ALB ACE
31 alport syndrome 3, autosomal dominant 32.0 COL4A4 COL4A3
32 hypertension, essential 32.0 UMOD PKD2 PKD1 NPHS2 CST3 COL4A5
33 urinary tract infection 32.0 UMOD ACE
34 acute kidney failure 32.0 UMOD CST3 ALB
35 glomerular disease 31.9 ALB ACE
36 acute cystitis 31.9 UMOD CST3 ALB ACE
37 interstitial nephritis 31.9 UMOD ALB ACE
38 pyelonephritis 31.8 UMOD ALB ACE
39 hypertensive nephropathy 31.8 CST3 ALB ACE
40 portal hypertension 31.8 PKHD1 ALB ACE
41 multicystic dysplastic kidney 31.7 PKD2 PKD1
42 urinary tract obstruction 31.7 UMOD ALB ACE
43 acute kidney tubular necrosis 31.6 UMOD CST3 ALB ACE
44 vesicoureteral reflux 1 31.6 UMOD CST3 ALB ACE
45 orthostatic intolerance 31.5 PKHD1 PKD2 PKD1 ACE
46 renal dysplasia, cystic 31.4 PKD1 CEP290
47 meckel syndrome, type 1 31.4 PKHD1 PKD2 PKD1 CEP290
48 chronic pyelonephritis 31.3 UMOD ALB ACE
49 sexual disorder 31.3 MIR141 ALB ACE
50 impotence 31.2 MIR141 ALB ACE

Comorbidity relations with Kidney Disease via Phenotypic Disease Network (PDN): (show top 50) (show all 51)


Active Peptic Ulcer Disease Acute Cystitis
Acute Kidney Failure Acute Myocardial Infarction
Alzheimer Disease Aortic Valve Disease 1
Bladder Neck Obstruction Bronchitis
Bronchopneumonia Cardiac Arrest
Cardiogenic Shock Decubitus Ulcer
Deficiency Anemia Diabetic Polyneuropathy
Encephalopathy Esophagitis
Familial Atrial Fibrillation First-Degree Atrioventricular Block
Generalized Atherosclerosis Gout
Heart Disease Hydronephrosis
Hypertension, Essential Hypoglycemia
Hypoglycemic Coma Hypothyroidism
Intermediate Coronary Syndrome Intestinal Obstruction
Iron Deficiency Anemia Malignant Essential Hypertension
Microvascular Complications of Diabetes 1 Mitral Valve Disease
Nephrosclerosis Paralytic Ileus
Peripheral Vascular Disease Polycystic Kidney Disease
Prostate Cancer Prostatic Hypertrophy
Protein-Energy Malnutrition Pulmonary Hypertension, Primary, 1
Pyelonephritis Renal Artery Atheroma
Renal Artery Disease Respiratory Failure
Schizophreniform Disorder Sinoatrial Node Disease
Swallowing Disorders Third-Degree Atrioventricular Block
Transient Cerebral Ischemia Tricuspid Valve Disease

Graphical network of the top 20 diseases related to Kidney Disease:



Diseases related to Kidney Disease
Sources

Symptoms & Phenotypes for Kidney Disease

About this section

UMLS symptoms related to Kidney Disease:


polyuria

MGI Mouse Phenotypes related to Kidney Disease:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.07 ACE ALB CEP290 COL4A3 COL4A5 CRB2
2 homeostasis/metabolism MP:0005376 10 ACE ALB CEP290 COL4A3 COL4A4 COL4A5
3 mortality/aging MP:0010768 9.77 ACE ALB CEP290 COL4A3 COL4A4 COL4A5
4 renal/urinary system MP:0005367 9.4 ACE ALB CEP290 COL4A3 COL4A4 COL4A5
Sources

Drugs & Therapeutics for Kidney Disease

About this section

Drugs for Kidney Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 845)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Acarbose Approved, Investigational Phase 4 56180-94-0 441184
2
Hydralazine Approved Phase 4 86-54-4 3637
3
Peginterferon alfa-2b Approved Phase 4 215647-85-1, 99210-65-8
4
Digoxin Approved Phase 4 20830-75-5 30322 2724385
5
Moxonidine Approved, Investigational Phase 4 75438-57-2 4810
6
Zaleplon Approved, Illicit, Investigational Phase 4 151319-34-5 5719
7
Capsaicin Approved Phase 4 404-86-4 1548943
8
Amiodarone Approved, Investigational Phase 4 1951-25-3 2157
9
Isosorbide Dinitrate Approved, Investigational Phase 4 87-33-2 6883
10
AT-101 Approved, Investigational Phase 4 90141-22-3, 652-67-5 12597
11
alemtuzumab Approved, Investigational Phase 4 216503-57-0
12
carbamide peroxide Approved Phase 4 124-43-6
13
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
14
Doxazosin Approved Phase 4 74191-85-8 3157
15
Atenolol Approved Phase 4 29122-68-7 2249
16
Clonidine Approved Phase 4 4205-90-7 2803
17
Irbesartan Approved, Investigational Phase 4 138402-11-6 3749
18
Olmesartan Approved, Investigational Phase 4 144689-24-7, 144689-63-4 158781 130881
19
Metformin Approved Phase 4 657-24-9 14219 4091
20
Aminophylline Approved Phase 4 317-34-0 9433
21
Regadenoson Approved, Investigational Phase 4 313348-27-5 219024
22
Candesartan cilexetil Approved Phase 4 145040-37-5 2540
23
Bortezomib Approved, Investigational Phase 4 179324-69-7 387447 93860
24
Colchicine Approved Phase 4 64-86-8 6167 2833
25
Fondaparinux Approved, Investigational Phase 4 104993-28-4
26
Alprostadil Approved, Investigational Phase 4 745-65-3 149351 5280723
27
Insulin glargine Approved Phase 4 160337-95-1
28
Gliclazide Approved Phase 4 21187-98-4 3475
29
Pentoxifylline Approved, Investigational Phase 4 6493-05-6 4740
30
Cinacalcet Approved Phase 4 226256-56-0 156419
31
Telavancin Approved Phase 4 372151-71-8
32
Insulin aspart Approved Phase 4 116094-23-6 16132418
33
Hydroxyurea Approved Phase 4 127-07-1 3657
34
Nifedipine Approved Phase 4 21829-25-4 4485
35
Cefotaxime Approved Phase 4 63527-52-6 456256 5742673
36
Netilmicin Approved, Investigational Phase 4 56391-56-1 441306 6857423
37
Dibekacin Approved Phase 4 34493-98-6
38
Heparin Approved, Investigational Phase 4 9005-49-6 772 9812414
39
Phenprocoumon Approved, Investigational Phase 4 435-97-2 9908 54680692
40
Insulin glulisine Approved Phase 4 207748-29-6
41
Argatroban Approved, Investigational Phase 4 74863-84-6 152951
42
Donepezil Approved Phase 4 120014-06-4 3152
43
Ranolazine Approved, Investigational Phase 4 95635-55-5, 142387-99-3 56959
44
Oseltamivir Approved Phase 4 196618-13-0, 204255-11-8 65028
45
Theophylline Approved Phase 4 58-55-9 2153
46
Lamivudine Approved, Investigational Phase 4 134678-17-4 60825
47
Peginterferon alfa-2a Approved, Investigational Phase 4 198153-51-4 5360545
48
Liraglutide Approved Phase 4 204656-20-2 44147092
49
Lixisenatide Approved Phase 4 320367-13-3
50
Iodine Approved, Investigational Phase 4 7553-56-2 807

Interventional clinical trials:

(show top 50) (show all 4893)
# Name Status NCT ID Phase Drugs
1 Phase 4 Study of Medical Therapy Versus Medical Therapy Plus Renal Artery Stenting in Preventing the Progression of Renal Failure in Atherosclerotic Renovascular Disease Unknown status NCT01023373 Phase 4 Medical treatment
2 NAC in Preventing CIN in CRF Patients Who Need Enhanced CT Scan in ED Unknown status NCT00501475 Phase 4 NAC Bicarbonate
3 The Effects of Thiazolidinedione on the Diabetic Retinopathy and Nephropathy Unknown status NCT01175486 Phase 4 Actos (Pioglitazone);Acarbose
4 Phase 4 Study of Alprostadil Prevent Contrast Induced Nephropathy in Patients Receiving a Cardiac Catheterization Unknown status NCT01722513 Phase 4 Alprostadil ﹠control
5 Renoprotection by Combining Pentoxifylline and Angiotensin Blockade in Chronic Kidney Disease Unknown status NCT01377285 Phase 4 ARB;Pentoxifylline;Placebo (for Pentoxifylline)
6 Effect of Hydration With Sodium Bicarbonate for Long-Term Clinical Outcomes in Patients With Chronic Kidney Disease Undergoing an Emergent Coronary Procedure Unknown status NCT00716001 Phase 4 N-acetylcysteine
7 A Prospective Randomized, Double-Blind Parallel Group Trial To Assess The Efficacy And Safety Of Intravenous Dextrose 5% Solution Compare With Normal Saline (Standard Care) In Rinsing During Haemodialysis In Subjects With End Stage Renal Failure (ESRF) With Respect To Systolic Blood Pressure Control Over 3 Months Period. Unknown status NCT02590081 Phase 4 Dextrose 5%;normal saline
8 Evaluation of Nail Fold Microcirculation and Interventional Therapy in Patients With Chronic Renal Failure Unknown status NCT03682952 Phase 4 Alprostadil Injection;Beraprost sodium tablets
9 A comParison on Platelet Resistance With Ticagrelor or Standard-Dose Clopidogrel Study Among SeVerE Chronic Kidney Disease/ End-Stage-Renal-Disease Patients With Recent Acute Coronary Syndrome. Unknown status NCT02459288 Phase 4 Clopidogrel first;Ticagrelor first
10 Reduction or Discontinuation of Calcineurine Inhibitors With Conversion to Everolimus-Based Immunosuppresion to Alleviate Chronic Allograft Nephropathy (CAN) in Kidney Transplant Recipients: A Prospective Randomized Study Unknown status NCT00443508 Phase 4 adding Certican to therapy;reducing Tacrolimus
11 Periprocedural Administration of Folic Acid for Prevention of Contrast Induced Nephropathy in Patients Undergoing Coronary CTA/Angiography/Angioplasty Unknown status NCT02444013 Phase 4 Folic acid;Placebo
12 Phase 4 Study of Sarpogrelate That Prevent Contrast-induced Nephropathy Unknown status NCT01165567 Phase 4 sarpogrelate
13 Open Randomized Phase IV Study on Intravenous Iron in Anemic Patients With Chronic Kidney Disease Unknown status NCT00204256 Phase 4 Iron sucrose
14 The Effects of AST-120 on Endothelial Dysfunction in Patients With Chronic Kidney Disease Unknown status NCT01157260 Phase 4 Kremezin
15 Pulse Wave Velocity, Pulse Wave Morphology and Blocking of the Reninangiotensin System in Patients With Chronic Kidney Disease: An Interventional and Methodological Study Unknown status NCT00235287 Phase 4 Candesartan and enalapril;candesartan and enalapril;candesartan and enalapril;candesartan and enalapril
16 Effects of Cholecalciferol on Osteoprotegerin Levels and Other Clinical Outcomes in Chronic Kidney Disease Patients on Peritoneal Dialysis: a Randomized Controlled Trial Unknown status NCT02598635 Phase 4 Cholecalciferol;Placebo
17 Effects of an Exercise Program in Patients With Hypertensive Chronic Kidney Disease: a Randomized Clinical Trial Unknown status NCT01155128 Phase 4
18 A Randomized Prospective Trial of N-acetyl Cystein in Patients With Peritoneal Dialysis Unknown status NCT01111422 Phase 4 N-acetylcysteine
19 Effect of Ursodeoxycholic Acid on Peritoneal Function in Patients on Peritoneal Dialysis Unknown status NCT02338635 Phase 4 Ursodeoxycholic Acid
20 the Effect of Calcium Dobesilate on Non Dialysis Patients With Chronic Renal Failure Unknown status NCT03427944 Phase 4 Calcium Dobesilate group;Conventional Treatment group
21 Canadian Collaborative Group for the Prevention of Illness in Chronic Renal Disease. The Canadian Prevention of Renal and Cardiovascular Endpoints Trial Unknown status NCT00231803 Phase 4
22 The Effect of Far Infrared (FIR) Therapy on Access Flow of Arteriovenous (AV) Fistula, Echocardiographic Parameters and Endothelial Function in Patients With End Stage Renal Disease Unknown status NCT01138254 Phase 4
23 Effects of Non-Glucose-Based Peritoneal Dialysis Solution "EXTRANEAL" on Changes in Leptin Levels and Sympathetic Activity Induced by Conventional Glucose-Based Dialysate "DIANEAL" in Patients on Peritoneal Dialysis Unknown status NCT01228279 Phase 4
24 Study on the Effect of Hyperuricaemia on Chronic Renal Disease and Intervention Unknown status NCT03425708 Phase 4 20mg Febuxostat;40mg Febuxostat
25 Marinobufagenin as a Target for DIGIBIND in Hypertensive Patients With End-stage Renal Disease Unknown status NCT00852787 Phase 4 Digoxin immune fab;Placebo
26 Sympathetic Nervous System Inhibition for the Treatment of Diabetic Nephropathy Unknown status NCT01094769 Phase 4 Moxonidine;Placebo
27 Effect of Intravenous and Oral Therapy With Sulodexide on Albuminuria in Type 2 Diabetic Patients Unknown status NCT01316068 Phase 4 intravenous use of sulodexide followed by oral use;use of sulodexide orally only
28 Effect of Sarpogrelate On the Nephropathy in Type 2 Diabetes Unknown status NCT01869881 Phase 4 Anplag(Sarpogrelate);Placebo
29 Phase 4 Study of Mechanisms of Low Protein Diet Supplemented With Ketoanalogs on Reducing Proteinuria and Maintaining Nutritional Status in Type 2 Diabetic Nephropathy Unknown status NCT01300273 Phase 4
30 Clinical Trial Technology Development for the Validation of Surrogate Prognostic Markers in Patients With Diabetic Nephropathy Unknown status NCT01673204 Phase 4 Calcitriol;Placebo
31 Effect of Aldosterone Antagonism in the Reduction of Albuminuria and Diastolic Disfunction of Patients With Diabetic Nephropathy. Unknown status NCT00870402 Phase 4 Spironolactone;Placebo
32 Prevention of Contrast Nephropathy During Diagnostic Coronary Angiogram or PCI With Hydratation Based on LEVDP Unknown status NCT00584350 Phase 4
33 Calcineurin Inhibitor Minimisation in Renal Transplant Recipients With Stable Allograft Function: A Prospective Randomised Controlled Trial Unknown status NCT00541814 Phase 4 Cyclosporine
34 A Randomized, Prospective, Open-Label Study of Rituximab in the Treatment of Recurrent IgA Nephropathy With Active Endocapillary Proliferation Pathology Unknown status NCT02571842 Phase 4 Intravenous Rituximab;ACEI/ARB and corticosteroids
35 Preventive Effect of the PRetreatment With pItavastatiN on Contrast-Induced Nephropathy in Patients With RenaL Dysfunction UndErgoing Coronary Angiography/Intervention (PRINCIPLE-II Study) Unknown status NCT01871792 Phase 4 Pitavastatin;Placebo
36 Safety of Add on Aliskiren to ACEI and ARB Treatment in Type 2 Diabetes With Nephropathy Unknown status NCT00949351 Phase 4 Aliskiren 300mg/d
37 A Prospective Randomized, Controlled, Open-labeled Trial of Prednisone Plus Cyclophosphamide in Patients With Advanced-stage IgA Nephropathy Unknown status NCT01758120 Phase 4 prednisone plus cyclophosphamide;Prednisone alone
38 Hydroxychloroquine Sulfate Alleviates Persistent Proteinuria in IgA Nephropathy:a Single Center Prospective Randomized Controlled Study Unknown status NCT02765594 Phase 4 Hydroxychloroquine Sulfate;Valsartan
39 Preventive Strategies of REnal Insufficiency in Patients With Diabetes Undergoing InterVENTion or Arteriography(PREVENT Trial) Unknown status NCT00950079 Phase 4 Sodium bicarbonate;saline
40 Efficacy and Safety of Abelmoschus Manihot for IgA Nephropathy: a Multicentre, Double-blind, Double-dummy, Randomized Controlled Trial Unknown status NCT02231125 Phase 4 Losartan;Abelmoschus manihot
41 Multi-center, Randomized, Open Label, Comparative, Phase IV Study to Evaluate the Efficacy and Safety of a Combination of Mycophenolate Mofetil and Corticosteroid for 48 Weeks in Advanced IgA Nephropathy Unknown status NCT02981212 Phase 4 Mycophenolate Mofetil;ACE inhibitor;Corticosteroid;ARB
42 A Prospective Randomized, Controlled Trial of Mycophenolate Mofetil Plus Steroid in the Treatment Of Patients With Progressive Idiopathic Membranous Nephropathy Unknown status NCT03170323 Phase 4 Mycophenolate Mofetil;Cyclosporins
43 N-Acetylcysteine to Prevent Contrast-Induced Nephropathy in Acute Coronary Syndromes Unknown status NCT00939913 Phase 4 intravenous NAC;Placebo
44 A Prospective, Randomized, Two Period, With an Intermediate Wash Out Period, Cross-over Study to Compare the Effects of Either Combined Therapy With Ramipril and Clopidogrel or Ramipril Monotherapy on Oxidative Stress, Vascular Inflammation and Endothelial Dysfunction in Patients With Type 2 Diabetes and Diabetic Nephropathy Unknown status NCT01743014 Phase 4 Ramipril;Clopidogrel
45 Intensive Medical Treatment for Nephropathy Caused by Type 2 Diabetes With Hypertension Unknown status NCT00407680 Phase 4 Intensive therapy Valsartan,Fluvastatin
46 Neutrophil gElatinase-associated Lipocalin alloWs Intensive treatMent Of cOntrast Induced Nephropathy in Patients With Urgent/Emergency Percutaneous Coronary Intervention Unknown status NCT01491243 Phase 4 Intensive treatment with sodium bicarbonate;Standard treatment with saline infusion
47 The Metabolic and Anti-Inflammatory Effects of Combined Ezetimibe and Simvastin Therapy, as Compared to Simvastatin Alone, in Patients With Chronic Proteinuric Nephropathy Unknown status NCT00861731 Phase 4 simvastatin;EZE/simvastatin;EZE/simvastatin
48 Preventing Contrast Induced Nephropathy After Transcatheter Aortic Valve Replacement Unknown status NCT03121053 Phase 4 sodium bicarbonate;hypotone saline
49 Prospective Trial of Conversion From Tacrolimus to Sirolimus in African American Renal Transplant Recipients With Chronic Allograft Nephropathy Unknown status NCT00999258 Phase 4 sirolimus
50 The Change of Urinary Angiotensinogen Excretion After Valsartan Treatment in Chronic Kidney Diseases Patients With Persistent Proteinuria Unknown status NCT00858299 Phase 4 valsartan

Search NIH Clinical Center for Kidney Disease

Inferred drug relations via UMLS 71 / NDF-RT 51 :


Albumin Human, USP
ALBUMIN,HUMAN INJ
Dopamine
Dopamine Hydrochloride

Cochrane evidence based reviews: kidney diseases

Sources

Genetic Tests for Kidney Disease

About this section

Genetic tests related to Kidney Disease:

# Genetic test Affiliating Genes
1 Nephropathy 29
2 Abnormality of the Kidney 29
Sources

Anatomical Context for Kidney Disease

About this section

The Foundational Model of Anatomy Ontology organs/tissues related to Kidney Disease:

19
Kidney

MalaCards organs/tissues related to Kidney Disease:

40
Kidney, Endothelial, Bone, Liver, Bone Marrow, Neutrophil, Skin
Sources

Publications for Kidney Disease

About this section

Articles related to Kidney Disease:

(show top 50) (show all 62521)
# Title Authors PMID Year
1
Chronic kidney disease and cardiovascular mortality in patients with atrial fibrillation: European Society of Hypertension project - ESH A Fib. 42 61
33466138 2021
2
Angiotensin-converting enzyme 2 and COVID-19 in cardiorenal diseases. 42
33399851 2021
3
Postoperative acute kidney injury and early and long-term mortality in acute aortic dissection patients: A meta-analysis. 42
33466119 2021
4
Imaging Characterization of Renal Masses. 42
33435540 2021
5
Baseline serum triglyceride predicts early-onset peritonitis and prognosis in incident CAPD patients. 42
33466123 2021
6
Treatment of Rare Inflammatory Kidney Diseases: Drugs Targeting the Terminal Complement Pathway. 42
33362783 2020
7
miR-200a Prevents renal fibrogenesis through repression of TGF-β2 expression. 47
20952520 2011
8
Tumor necrosis factor (TNF-alpha) and C-reactive protein (CRP) are positively associated with the risk of chronic kidney disease in patients with type 2 diabetes. 54 61
20499416 2010
9
Evidence for a role of uromodulin in chronic kidney disease progression. 61 54
20075439 2010
10
Effect of paricalcitol and cinacalcet on serum phosphate, FGF-23, and bone in rats with chronic kidney disease. 61 54
20200094 2010
11
An integrative view on the role of TGF-beta in the progressive tubular deletion associated with chronic kidney disease. 54 61
20336053 2010
12
Sulodexide ameliorates early but not late kidney disease in models of radiation nephropathy and diabetic nephropathy. 61 54
20061322 2010
13
Increment and impairment of adiponectin in renal failure. 54 61
20035033 2010
14
An aid to the diagnosis of genetic disorders underlying adult-onset renal failure: a literature review. 54 61
20497759 2010
15
Performance evaluation of a particle-enhanced turbidimetric cystatin C assay using the Abbott Aeroset analyser and assessment of cystatin C-based equations for estimating glomerular filtration rate in chronic kidney disease. 61 54
20037185 2010
16
Serum creatinine, cystatin C, and beta-trace protein in diagnostic staging and predicting progression of primary nondiabetic chronic kidney disease. 54 61
20224047 2010
17
Is collapsing C1q nephropathy another MYH9-associated kidney disease? A case report. 54 61
20116156 2010
18
Predicting potential survival benefit of renal transplantation in patients with chronic kidney disease. 61 54
20351122 2010
19
Pentoxifylline improves haemoglobin and interleukin-6 levels in chronic kidney disease. 61 54
20470305 2010
20
Is Fibroblast Growth Factor-23 a novel marker for phosphate burden in chronic kidney disease with prognostic implications? 54 61
20503017 2010
21
Circulating levels of osteopontin are closely related to glomerular filtration rate and cardiovascular risk markers in patients with chronic kidney disease. 61 54
20486990 2010
22
Terlipressin therapy for renal failure in cirrhosis. 54 61
19952764 2010
23
Molecular diagnostics for autosomal dominant polycystic kidney disease. 54 61
20177400 2010
24
The circulating inactive form of matrix gla protein is a surrogate marker for vascular calcification in chronic kidney disease: a preliminary report. 61 54
20133489 2010
25
Aldose reductase inhibitors and diabetic kidney disease. 54 61
20336588 2010
26
The influence of glomerular filtration rate and age on fibroblast growth factor 23 serum levels in pediatric chronic kidney disease. 61 54
20157196 2010
27
Antagonists of bone morphogenetic proteins in kidney disease. 54 61
20178045 2010
28
Diagnostic accuracy of various glomerular filtration rates estimating equations in patients with chronic kidney disease and diabetes. 61 54
20368098 2010
29
Plasma interleukin-6 is independently associated with mortality in both hemodialysis and pre-dialysis patients with chronic kidney disease. 61 54
20016471 2010
30
HMG CoA reductase inhibition and endothelial function in children with chronic kidney disease (CKD)--a pilot study. 54 61
20050832 2010
31
Erythropoietin response to anemia and its association with autonomic neuropathy in type 2 diabetic patients without advanced renal failure. 54 61
19303331 2010
32
Control of secondary hyperparathyroidism by vitamin D receptor agonists in chronic kidney disease. 54 61
20133492 2010
33
Mechanisms linking obesity, chronic kidney disease, and fatty liver disease: the roles of fetuin-A, adiponectin, and AMPK. 54 61
20150538 2010
34
Visfatin is increased in chronic kidney disease patients with poor appetite and correlates negatively with fasting serum amino acids and triglyceride levels. 54 61
19948877 2010
35
A prospective study of fibroblast growth factor-23 in children with chronic kidney disease. 54 61
19929273 2010
36
Alterations of retinol-binding protein 4 species in patients with different stages of chronic kidney disease and their relation to lipid parameters. 54 61
20097162 2010
37
Genetic variation at selected SNPs in the leptin gene and association of alleles with markers of kidney disease in a Xhosa population of South Africa. 54 61
20140086 2010
38
PKHD1 sequence variations in 78 children and adults with autosomal recessive polycystic kidney disease and congenital hepatic fibrosis. 54 61
19914852 2010
39
FGF23-parathyroid interaction: implications in chronic kidney disease. 54 61
20010546 2010
40
CRP polymorphisms and progression of chronic kidney disease in African Americans. 54 61
19965533 2010
41
[Chronic kidney disease and the aldosterone/mineralocorticoid receptor system]. 61 54
20415233 2010
42
The relation of C--reactive protein to chronic kidney disease in African Americans: the Jackson Heart Study. 54 61
20078870 2010
43
Is cystatin C a useful marker in the detection of diabetic kidney disease? 61 54
19887833 2010
44
Plasma adiponectin levels in chronic kidney disease patients: relation with molecular inflammatory profile and metabolic status. 54 61
19359150 2010
45
Alport retinopathy results from "severe" COL4A5 mutations and predicts early renal failure. 54 61
19965530 2010
46
Effect of pentoxifylline on proteinuria, markers of tubular injury and oxidative stress in non-diabetic patients with chronic kidney disease - placebo controlled, randomized, cross-over study. 54 61
20309434 2010
47
Susceptibility genes in common complex kidney disease. 61 54
19838113 2010
48
Influence of chronic renal failure on acid secretion in isolated gastric mucosal cells from human biopsies. 61 54
20380354 2010
49
Elevated brain natriuretic peptide is associated with abnormal heart geometry in children with chronic kidney disease. 61 54
20234137 2010
50
Estimating glomerular filtration rate using the new CKD-EPI equation and other equations in patients with autosomal dominant polycystic kidney disease. 54 61
19887788 2010
Sources

Variations for Kidney Disease

About this section

ClinVar genetic disease variations for Kidney Disease:

6 (show all 13)
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 CEP290 NM_025114.4(CEP290):c.5493del (p.Ala1832fs) Deletion Pathogenic 56739 rs386834158 12:88471567-88471567 12:88077790-88077790
2 CEP290 NM_025114.4(CEP290):c.3104-2A>G SNV Pathogenic 374210 rs773386777 12:88487754-88487754 12:88093977-88093977
3 COL4A5 NM_033380.2(COL4A5):c.1424-2_1430delAGGTGACAA Deletion Pathogenic 523544 rs1556411578 X:107838737-107838745 X:108595507-108595515
4 TSC1 NM_000368.5(TSC1):c.989dup (p.Ser331fs) Duplication Pathogenic 49135 rs118203478 9:135786879-135786880 9:132911492-132911493
5 PKD1 NM_001009944.3(PKD1):c.3785A>G (p.His1262Arg) SNV Likely pathogenic 374206 rs1057518976 16:2161383-2161383 16:2111382-2111382
6 PKD1 NM_001009944.3(PKD1):c.7904dup (p.Arg2636fs) Duplication Likely pathogenic 689540 rs1596536873 16:2155434-2155435 16:2105433-2105434
7 MEFV NM_000243.3(MEFV):c.2084A>G (p.Lys695Arg) SNV Likely pathogenic 2547 rs104895094 16:3293403-3293403 16:3243403-3243403
8 TMEM67 NM_153704.6(TMEM67):c.1321C>T (p.Arg441Cys) SNV Likely pathogenic 217725 rs752362727 8:94798483-94798483 8:93786255-93786255
9 PKD1 NM_001009944.3(PKD1):c.3890_3891insCAC (p.Arg1298_Val1299insThr) Insertion Likely pathogenic 620077 rs1567202189 16:2161277-2161278 16:2111276-2111277
10 INF2 NM_022489.4(INF2):c.658G>A (p.Glu220Lys) SNV Likely pathogenic 523533 rs530391015 14:105169782-105169782 14:104703445-104703445
11 TMEM67 NM_153704.6(TMEM67):c.1843T>C (p.Cys615Arg) SNV Likely pathogenic 1383 rs201893408 8:94808198-94808198 8:93795970-93795970
12 PAX9 Deletion Uncertain significance 635872 14:37145358-37162210
13 CPT2 NM_000098.3(CPT2):c.1766C>T (p.Thr589Met) SNV Uncertain significance 804352 rs756414686 1:53679056-53679056 1:53213384-53213384

Copy number variations for Kidney Disease from CNVD:

7 (show all 21)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 22040 1 16450000 16950000 Duplication renal disease
2 37196 1 8700000 16000000 Deletion renal disease
3 76925 13 38159172 38359267 Copy number FREM2 renal disease
4 95843 15 81011700 83540700 Deletion renal disease
5 97939 16 14780000 16770000 Deletion renal disease
6 110304 17 31836750 33582750 Microdeletion renal disease
7 110305 17 31836750 33582750 Microdeletion CCL3L1 renal disease
8 110306 17 31836750 33582750 Microdeletion CCL4L1 renal disease
9 110307 17 31836750 33582750 Microdeletion HNF1B renal disease
10 110539 17 33120546 33179209 Copy number HNF1B renal disease
11 110540 17 33120546 33179209 Copy number HNF1B renal disease
12 110544 17 33120546 33179209 Deletion HNF1B renal disease
13 115163 17 55061600 55218400 Duplication renal disease
14 127179 19 28500000 63811651 Microdeletion renal disease
15 127247 19 30200000 37100000 Deletion renal disease
16 128207 19 40300000 43000000 Deletion renal disease
17 160230 22 11800000 24300000 Deletion renal disease
18 189838 4 79197747 79684447 Copy number FRAS1 renal disease
19 191442 5 1 12100000 Duplication renal disease
20 222025 7 148600000 158550000 Deletion renal disease
21 264973 X 71600000 71800000 Duplication renal disease
Sources

Expression for Kidney Disease

About this section
Search GEO for disease gene expression data for Kidney Disease.
Sources

Pathways for Kidney Disease

About this section

Pathways related to Kidney Disease according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Amoebiasis 36
11.62 COL4A5 COL4A4 COL4A3
2
AGE-RAGE signaling pathway in diabetic complications 36
11.58 COL4A5 COL4A4 COL4A3
3
Small cell lung cancer 36
11.51 COL4A5 COL4A4 COL4A3
4
Cell adhesion_ECM remodeling 23
11.28 COL4A5 COL4A4 COL4A3
5
Cell adhesion_Plasmin signaling 23
11.12 COL4A5 COL4A4 COL4A3
6
Cell adhesion_Endothelial cell contacts by non-junctional mechanisms 23
10.93 COL4A5 COL4A4 COL4A3
7
Primary Focal Segmental Glomerulosclerosis FSGS 1
10.79 NPHS2 COL4A5 COL4A4 COL4A3
8
NCAM1 interactions 65
10.7